SIMPLIFIER.NET - FHIRPath Playground

FHIRPath

If you Log in or sign up, you can edit this script yourself.

{
  "resourceType": "ValueSet",
  "id": "prescriptionodbreasonforuse",
  "url": "https://fhir.infoway-inforoute.ca/ValueSet/prescriptionodbreasonforuse",
  "identifier": [
    {
      "id": "DHDR-PODBRFU"
    }
  ],
  "version": "20161017",
  "name": "PrescriptionODBReasonForUse",
  "publisher": "Canada Health Infoway",
  "status": "active",
  "contact": [
    {
      "name": "National Standards Release Centre",
      "telecom": [
        {
          "system": "url",
          "value": "http://www.infoway-inforoute.ca"
        },
        {
          "system": "email",
          "value": "standards@infoway-inforoute.ca"
        }
      ]
    }
  ],
  "description": "Prescription ODB Reason for Use..\n\nThis resource is an informative value set; a [normative subset](https://tgateway.infoway-inforoute.ca/vs/prescriptionodbreasonforuse) containing the expanded values can be found on Canada Health Infoway's [Terminology Gateway](https://tgateway.infoway-inforoute.ca).",
  "expansion": {
    "identifier": "urn:uuid:7515e097-368a-40f8-80b8-6296dca8a539",
    "timestamp": "2022-01-14T19:45:08+00:00",
    "total": 229,
    "contains": [
      {
        "abstract": false,
        "code": "1",
        "display": "For the treatment of patients disabled by moderate to severe neurogenic orthostatic hypotension (i.e. drop in systolic BP less than or equal to 20mm Hg from supine to standing position), in whom conventional nonpharmacologic and pharmacologic (i.e. fludrocortisone) therapies have proven ineffective or are poorly tolerated.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "For the treatment of patients disabled by moderate to severe neurogenic orthostatic hypotension (i.e. drop in systolic BP less than or equal to 20mm Hg from supine to standing position), in whom conventional nonpharmacologic and pharmacologic (i.e. fludrocortisone) therapies have proven ineffective or are poorly tolerated."
          }
        ]
      },
      {
        "abstract": false,
        "code": "3",
        "display": "For the treatment of non-allergic vasomotor rhinitis",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "For the treatment of non-allergic vasomotor rhinitis"
          }
        ]
      },
      {
        "abstract": false,
        "code": "10",
        "display": "For the treatment of strabismus and blepharospasm associated with dystonia, including benign essential blepharospasm or VII nerve disorders in patients 12 years of age or older.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "For the treatment of strabismus and blepharospasm associated with dystonia, including benign essential blepharospasm or VII nerve disorders in patients 12 years of age or older."
          }
        ]
      },
      {
        "abstract": false,
        "code": "12",
        "display": "For the treatment of CMV retinitis secondary to AIDS and other immunosuppressive syndromes.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "For the treatment of CMV retinitis secondary to AIDS and other immunosuppressive syndromes."
          }
        ]
      },
      {
        "abstract": false,
        "code": "23",
        "display": "As adjunctive therapy in the treatment of seizure disorders where control by other listed anticonvulsants has been unsatisfactory.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "As adjunctive therapy in the treatment of seizure disorders where control by other listed anticonvulsants has been unsatisfactory."
          }
        ]
      },
      {
        "abstract": false,
        "code": "28",
        "display": "For hairy cell leukemia.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "For hairy cell leukemia."
          }
        ]
      },
      {
        "abstract": false,
        "code": "29",
        "display": "For Kaposi's Sarcoma.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "For Kaposi's Sarcoma."
          }
        ]
      },
      {
        "abstract": false,
        "code": "33",
        "display": "For patients with severely impaired renal function refractory to conventional dosages of the drug.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "For patients with severely impaired renal function refractory to conventional dosages of the drug."
          }
        ]
      },
      {
        "abstract": false,
        "code": "42",
        "display": "As adjunctive therapy to improve the neurologic outcome following subarachnoid haemorrhage during the acute management period (within 4 days of haemorrhage).",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "As adjunctive therapy to improve the neurologic outcome following subarachnoid haemorrhage during the acute management period (within 4 days of haemorrhage)."
          }
        ]
      },
      {
        "abstract": false,
        "code": "43",
        "display": "As prophylaxis of ischemia if surgery is delayed.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "As prophylaxis of ischemia if surgery is delayed."
          }
        ]
      },
      {
        "abstract": false,
        "code": "49",
        "display": "For patients with objective evidence of keratoconjunctivitis sicca as confirmed by filamentary keratopathy on slit lamp examination or biopsy..",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "For patients with objective evidence of keratoconjunctivitis sicca as confirmed by filamentary keratopathy on slit lamp examination or biopsy.."
          }
        ]
      },
      {
        "abstract": false,
        "code": "60",
        "display": "For patients with migraine headaches who have not responded to propranolol.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "For patients with migraine headaches who have not responded to propranolol."
          }
        ]
      },
      {
        "abstract": false,
        "code": "61",
        "display": "For patients who have tried propranolol and experienced significant adverse effects.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "For patients who have tried propranolol and experienced significant adverse effects."
          }
        ]
      },
      {
        "abstract": false,
        "code": "62",
        "display": "For patients in whom propranolol is contraindicated.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "For patients in whom propranolol is contraindicated."
          }
        ]
      },
      {
        "abstract": false,
        "code": "64",
        "display": "For patients with Parkinson's disease who have been treated with conventional therapy (Prolopa or conventional Sinemet), and experienced adverse effects related to drug level fluctuations, such as ON/OFF or wearing off phenomena.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "For patients with Parkinson's disease who have been treated with conventional therapy (Prolopa or conventional Sinemet), and experienced adverse effects related to drug level fluctuations, such as ON/OFF or wearing off phenomena."
          }
        ]
      },
      {
        "abstract": false,
        "code": "65",
        "display": "For patients presently requiring anti-parkinsonian drug administration (levodopa/carbidopa) more than three times daily.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "For patients presently requiring anti-parkinsonian drug administration (levodopa/carbidopa) more than three times daily."
          }
        ]
      },
      {
        "abstract": false,
        "code": "67",
        "display": "For patients who have been tried on conventional carbamazepine with unsatisfactory results due to adverse effects or poor control of symptoms.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "For patients who have been tried on conventional carbamazepine with unsatisfactory results due to adverse effects or poor control of symptoms."
          }
        ]
      },
      {
        "abstract": false,
        "code": "76",
        "display": "For the treatment of patients with critical limb ischemia (with arterial ulcers, gangrene and/or rest pain) and documented arterial vascular disease.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "For the treatment of patients with critical limb ischemia (with arterial ulcers, gangrene and/or rest pain) and documented arterial vascular disease."
          }
        ]
      },
      {
        "abstract": false,
        "code": "91",
        "display": "For the treatment of emesis in cancer patients receiving highly emetogenic chemotherapy.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "For the treatment of emesis in cancer patients receiving highly emetogenic chemotherapy."
          }
        ]
      },
      {
        "abstract": false,
        "code": "92",
        "display": "For patients receiving intravenous chemotherapy or radiation therapy who have not experienced adequate control with other available anti-emetics.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "For patients receiving intravenous chemotherapy or radiation therapy who have not experienced adequate control with other available anti-emetics."
          }
        ]
      },
      {
        "abstract": false,
        "code": "93",
        "display": "For patients receiving intravenous chemotherapy or radiation therapy who experience intolerable side effects with other anti- emetics.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "For patients receiving intravenous chemotherapy or radiation therapy who experience intolerable side effects with other anti- emetics."
          }
        ]
      },
      {
        "abstract": false,
        "code": "103",
        "display": "Patients with a CD4+ cell count less than 200/mm3 with an AIDS-defining diagnosis;",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "Patients with a CD4+ cell count less than 200/mm3 with an AIDS-defining diagnosis;"
          }
        ]
      },
      {
        "abstract": false,
        "code": "104",
        "display": "Patients with a CD4+ cell count less than 100/mm3 without an AIDS-defining diagnosis.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "Patients with a CD4+ cell count less than 100/mm3 without an AIDS-defining diagnosis."
          }
        ]
      },
      {
        "abstract": false,
        "code": "110",
        "display": "An ileostomy or a colostomy;.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "An ileostomy or a colostomy;."
          }
        ]
      },
      {
        "abstract": false,
        "code": "111",
        "display": "Bowel resection, including short bowel syndrome;",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "Bowel resection, including short bowel syndrome;"
          }
        ]
      },
      {
        "abstract": false,
        "code": "112",
        "display": "Inflammatory Bowel Diseases, i.e. Crohn's Disease and Ulcerative Colitis;",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "Inflammatory Bowel Diseases, i.e. Crohn's Disease and Ulcerative Colitis;"
          }
        ]
      },
      {
        "abstract": false,
        "code": "113",
        "display": "Cancer, including chemotherapy or radiation therapy;",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "Cancer, including chemotherapy or radiation therapy;"
          }
        ]
      },
      {
        "abstract": false,
        "code": "114",
        "display": "HIV/AIDS;",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "HIV/AIDS;"
          }
        ]
      },
      {
        "abstract": false,
        "code": "115",
        "display": "Acute diarrhea in patients in congregated housing, i.e. Long Term Care Facilities (LTCF), or for patients receiving Home Care;",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "Acute diarrhea in patients in congregated housing, i.e. Long Term Care Facilities (LTCF), or for patients receiving Home Care;"
          }
        ]
      },
      {
        "abstract": false,
        "code": "124",
        "display": "Replacement therapy for pancreatic insufficiency secondary to pancreatic surgery (resection).",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "Replacement therapy for pancreatic insufficiency secondary to pancreatic surgery (resection)."
          }
        ]
      },
      {
        "abstract": false,
        "code": "125",
        "display": "Replacement therapy for pancreatic insufficiency due to chronic pancreatitis.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "Replacement therapy for pancreatic insufficiency due to chronic pancreatitis."
          }
        ]
      },
      {
        "abstract": false,
        "code": "126",
        "display": "Replacement therapy for pancreatic insufficiency due to carcinoma of the pancreas.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "Replacement therapy for pancreatic insufficiency due to carcinoma of the pancreas."
          }
        ]
      },
      {
        "abstract": false,
        "code": "130",
        "display": "To reduce the subjective symptoms and objective signs of cervical dystonia (spasmodic torticollis) in adults.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "To reduce the subjective symptoms and objective signs of cervical dystonia (spasmodic torticollis) in adults."
          }
        ]
      },
      {
        "abstract": false,
        "code": "132",
        "display": "For the treatment of asthma in patients who are using optimum anti-inflammatory treatment and are still experiencing breakthrough symptoms.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "For the treatment of asthma in patients who are using optimum anti-inflammatory treatment and are still experiencing breakthrough symptoms."
          }
        ]
      },
      {
        "abstract": false,
        "code": "136",
        "display": "As adjunctive therapy in the treatment of seizure disorders where control by other listed anticonvulsants has been unsatisfactory.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "As adjunctive therapy in the treatment of seizure disorders where control by other listed anticonvulsants has been unsatisfactory."
          }
        ]
      },
      {
        "abstract": false,
        "code": "147",
        "display": "Herpes zoster in patients 50 years of age or older, up to 72 hours after appearance of lesions. Dose: 500mg 3 times/day for 7 days.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "Herpes zoster in patients 50 years of age or older, up to 72 hours after appearance of lesions. Dose: 500mg 3 times/day for 7 days."
          }
        ]
      },
      {
        "abstract": false,
        "code": "159",
        "display": "Herpes zoster in patients 50 years of age or older, up to 72 hours after appearance of lesions. Dose: 1 gram 3 times/day for 7 days.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "Herpes zoster in patients 50 years of age or older, up to 72 hours after appearance of lesions. Dose: 1 gram 3 times/day for 7 days."
          }
        ]
      },
      {
        "abstract": false,
        "code": "170",
        "display": "For the treatment of conjunctivitis caused by susceptible strain(s) of Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pneumoniae and Hemophilus influenzae which is/are resistant or unresponsive to listed alternative agents.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "For the treatment of conjunctivitis caused by susceptible strain(s) of Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pneumoniae and Hemophilus influenzae which is/are resistant or unresponsive to listed alternative agents."
          }
        ]
      },
      {
        "abstract": false,
        "code": "171",
        "display": "As first line treatment of elevated intraocular pressure in patients who cannot tolerate an ophthalmic beta-blocking agent or where beta-blocking agents are contraindicated.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "As first line treatment of elevated intraocular pressure in patients who cannot tolerate an ophthalmic beta-blocking agent or where beta-blocking agents are contraindicated."
          }
        ]
      },
      {
        "abstract": false,
        "code": "172",
        "display": "As second line monotherapy or combination therapy in patients who do not have an adequate intraocular pressure lowering response to ophthalmic beta-blocking agents.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "As second line monotherapy or combination therapy in patients who do not have an adequate intraocular pressure lowering response to ophthalmic beta-blocking agents."
          }
        ]
      },
      {
        "abstract": false,
        "code": "173",
        "display": "For solid organ transplant and bone marrow transplant.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "For solid organ transplant and bone marrow transplant."
          }
        ]
      },
      {
        "abstract": false,
        "code": "175",
        "display": "In patients who cannot tolerate or have failed treatment with other oral hypoglycemic agents or in whom other oral hypoglycemic agents are contraindicated;",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "In patients who cannot tolerate or have failed treatment with other oral hypoglycemic agents or in whom other oral hypoglycemic agents are contraindicated;"
          }
        ]
      },
      {
        "abstract": false,
        "code": "176",
        "display": "In patients who require combination therapy with more than one oral hypoglycemic agent to control their serum glucose concentrations.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "In patients who require combination therapy with more than one oral hypoglycemic agent to control their serum glucose concentrations."
          }
        ]
      },
      {
        "abstract": false,
        "code": "177",
        "display": "For the treatment of psoriasis in patients who have failed, or are intolerant to, other systemic therapies, including methotrexate, acitretin or PUVA;",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "For the treatment of psoriasis in patients who have failed, or are intolerant to, other systemic therapies, including methotrexate, acitretin or PUVA;"
          }
        ]
      },
      {
        "abstract": false,
        "code": "178",
        "display": "For the treatment of rheumatoid arthritis in patients who have failed, or are intolerant to, other systemic therapies, including Disease-Modifying Antirheumatic Drugs (DMARDs).",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "For the treatment of rheumatoid arthritis in patients who have failed, or are intolerant to, other systemic therapies, including Disease-Modifying Antirheumatic Drugs (DMARDs)."
          }
        ]
      },
      {
        "abstract": false,
        "code": "180",
        "display": "For the hormonal treatment of metastatic breast cancer in hormone receptor positive post-menopausal women who have disease progression following tamoxifen therapy.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "For the hormonal treatment of metastatic breast cancer in hormone receptor positive post-menopausal women who have disease progression following tamoxifen therapy."
          }
        ]
      },
      {
        "abstract": false,
        "code": "183",
        "display": "NYHA Class II or III Congestive Heart Failure (CHF); and Currently being treated with an angiotensin converting enzyme (ACE) inhibitor, diuretics with or without digoxin, or previously treated, and failed these agents; and An ejection fraction less than or equal to 35%; and At least one episode of symptomatic CHF within a 12 month period while receiving optimal management.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "NYHA Class II or III Congestive Heart Failure (CHF); and Currently being treated with an angiotensin converting enzyme (ACE) inhibitor, diuretics with or without digoxin, or previously treated, and failed these agents; and An ejection fraction less than or equal to 35%; and At least one episode of symptomatic CHF within a 12 month period while receiving optimal management."
          }
        ]
      },
      {
        "abstract": false,
        "code": "186",
        "display": "For acute treatment of deep venous thrombosis (DVT), for a maximum of three weeks;",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "For acute treatment of deep venous thrombosis (DVT), for a maximum of three weeks;"
          }
        ]
      },
      {
        "abstract": false,
        "code": "187",
        "display": "For DVT in pregnant or lactating females;",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "For DVT in pregnant or lactating females;"
          }
        ]
      },
      {
        "abstract": false,
        "code": "188",
        "display": "For DVT in patients whom treatment with warfarin is not tolerated, or contraindicated;",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "For DVT in patients whom treatment with warfarin is not tolerated, or contraindicated;"
          }
        ]
      },
      {
        "abstract": false,
        "code": "189",
        "display": "For DVT in patients who have failed treatment with warfarin.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "For DVT in patients who have failed treatment with warfarin."
          }
        ]
      },
      {
        "abstract": false,
        "code": "190",
        "display": "For the prophylaxis of organ rejection in patients receiving allogeneic renal, cardiac or hepatic transplants.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "For the prophylaxis of organ rejection in patients receiving allogeneic renal, cardiac or hepatic transplants."
          }
        ]
      },
      {
        "abstract": false,
        "code": "191",
        "display": "For the treatment of psoriasis in patients who have failed topical corticosteroids alone, or are intolerant to topical corticosteroids.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "For the treatment of psoriasis in patients who have failed topical corticosteroids alone, or are intolerant to topical corticosteroids."
          }
        ]
      },
      {
        "abstract": false,
        "code": "201",
        "display": "For the treatment of chronic pain in patients who cannot tolerate, or have failed treatment with a listed long-acting opioid.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "For the treatment of chronic pain in patients who cannot tolerate, or have failed treatment with a listed long-acting opioid."
          }
        ]
      },
      {
        "abstract": false,
        "code": "202",
        "display": "For the treatment of thrush in immunocompromised patients (i.e. patients with malignancies and transplant recipients) who are unresponsive to nystatin or imidazole preparations;",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "For the treatment of thrush in immunocompromised patients (i.e. patients with malignancies and transplant recipients) who are unresponsive to nystatin or imidazole preparations;"
          }
        ]
      },
      {
        "abstract": false,
        "code": "203",
        "display": "For the treatment of oroesophageal candidiasis in immunocompromised patients (i.e. patients with malignancies and transplant recipients);",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "For the treatment of oroesophageal candidiasis in immunocompromised patients (i.e. patients with malignancies and transplant recipients);"
          }
        ]
      },
      {
        "abstract": false,
        "code": "204",
        "display": "For patients with disseminated candidiasis;",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "For patients with disseminated candidiasis;"
          }
        ]
      },
      {
        "abstract": false,
        "code": "205",
        "display": "For the treatment of acute cryptococcal meningitis.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "For the treatment of acute cryptococcal meningitis."
          }
        ]
      },
      {
        "abstract": false,
        "code": "215",
        "display": "For the treatment of emesis in cancer patients receiving highly emetogenic chemotherapy.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "For the treatment of emesis in cancer patients receiving highly emetogenic chemotherapy."
          }
        ]
      },
      {
        "abstract": false,
        "code": "216",
        "display": "For patients receiving intravenous chemotherapy or radiation therapy who have not experienced adequate control with other available anti-emetics.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "For patients receiving intravenous chemotherapy or radiation therapy who have not experienced adequate control with other available anti-emetics."
          }
        ]
      },
      {
        "abstract": false,
        "code": "217",
        "display": "For patients receiving intravenous chemotherapy or radiation therapy who experience intolerable side effects with other anti-emetics.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "For patients receiving intravenous chemotherapy or radiation therapy who experience intolerable side effects with other anti-emetics."
          }
        ]
      },
      {
        "abstract": false,
        "code": "218",
        "display": "For the treatment of emesis in patients receiving radiation therapy which consists of single fraction treatment to the abdominal cavity, hemi-body irradiation and total body irradiation.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "For the treatment of emesis in patients receiving radiation therapy which consists of single fraction treatment to the abdominal cavity, hemi-body irradiation and total body irradiation."
          }
        ]
      },
      {
        "abstract": false,
        "code": "219",
        "display": "Who are known to be, or become, intolerant of ASA;",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "Who are known to be, or become, intolerant of ASA;"
          }
        ]
      },
      {
        "abstract": false,
        "code": "220",
        "display": "Where ASA is contraindicated;",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "Where ASA is contraindicated;"
          }
        ]
      },
      {
        "abstract": false,
        "code": "221",
        "display": "Who continue to have TIA or stroke symptoms while being treated with ASA.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "Who continue to have TIA or stroke symptoms while being treated with ASA."
          }
        ]
      },
      {
        "abstract": false,
        "code": "224",
        "display": "Fecal incontinence.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "Fecal incontinence."
          }
        ]
      },
      {
        "abstract": false,
        "code": "225",
        "display": "Replacement therapy for pancreatic insufficiency due to cystic fibrosis.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "Replacement therapy for pancreatic insufficiency due to cystic fibrosis."
          }
        ]
      },
      {
        "abstract": false,
        "code": "235",
        "display": "For the treatment of vaginal candidiasis. Dose: 150mg orally once daily for 1 day.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "For the treatment of vaginal candidiasis. Dose: 150mg orally once daily for 1 day."
          }
        ]
      },
      {
        "abstract": false,
        "code": "236",
        "display": "For the treatment of Paget's disease;",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "For the treatment of Paget's disease;"
          }
        ]
      },
      {
        "abstract": false,
        "code": "237",
        "display": "For the management of hypercalcemia of malignancy.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "For the management of hypercalcemia of malignancy."
          }
        ]
      },
      {
        "abstract": false,
        "code": "240",
        "display": "For the symptomatic relief of treatment induced mucositis in cancer patients.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "For the symptomatic relief of treatment induced mucositis in cancer patients."
          }
        ]
      },
      {
        "abstract": false,
        "code": "256",
        "display": "Patients who have a tracheostomy;",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "Patients who have a tracheostomy;"
          }
        ]
      },
      {
        "abstract": false,
        "code": "257",
        "display": "Patients with cystic fibrosis in whom nebulizer therapy is indicated;",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "Patients with cystic fibrosis in whom nebulizer therapy is indicated;"
          }
        ]
      },
      {
        "abstract": false,
        "code": "258",
        "display": "Patients with severe mental or physical disabilities;",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "Patients with severe mental or physical disabilities;"
          }
        ]
      },
      {
        "abstract": false,
        "code": "259",
        "display": "Patients who have previously used nebulizer therapy within the last 12 month period.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "Patients who have previously used nebulizer therapy within the last 12 month period."
          }
        ]
      },
      {
        "abstract": false,
        "code": "260",
        "display": "Children aged 6 years or less;",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "Children aged 6 years or less;"
          }
        ]
      },
      {
        "abstract": false,
        "code": "261",
        "display": "Patients who have a tracheostomy;",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "Patients who have a tracheostomy;"
          }
        ]
      },
      {
        "abstract": false,
        "code": "262",
        "display": "Patients with cystic fibrosis in whom nebulizer therapy is indicated;",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "Patients with cystic fibrosis in whom nebulizer therapy is indicated;"
          }
        ]
      },
      {
        "abstract": false,
        "code": "263",
        "display": "Patients with severe mental or physical disabilities;",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "Patients with severe mental or physical disabilities;"
          }
        ]
      },
      {
        "abstract": false,
        "code": "264",
        "display": "Patients who have previously used nebulizer therapy within the last 12 month period.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "Patients who have previously used nebulizer therapy within the last 12 month period."
          }
        ]
      },
      {
        "abstract": false,
        "code": "265",
        "display": "Individuals must have a known hypersensitivity to the preservative in the bulk solution, and have a tracheostomy;",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "Individuals must have a known hypersensitivity to the preservative in the bulk solution, and have a tracheostomy;"
          }
        ]
      },
      {
        "abstract": false,
        "code": "266",
        "display": "Individuals must have a known hypersensitivity to the preservative in the bulk solution, and be patients with cystic fibrosis in whom nebulizer therapy is indicated;.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "Individuals must have a known hypersensitivity to the preservative in the bulk solution, and be patients with cystic fibrosis in whom nebulizer therapy is indicated;."
          }
        ]
      },
      {
        "abstract": false,
        "code": "267",
        "display": "Individuals must have a known hypersensitivity to the preservative in the bulk solution, and have severe mental or physical disabilities;",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "Individuals must have a known hypersensitivity to the preservative in the bulk solution, and have severe mental or physical disabilities;"
          }
        ]
      },
      {
        "abstract": false,
        "code": "268",
        "display": "Patients who have previously used nebulizer therapy within the last 12 month period.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "Patients who have previously used nebulizer therapy within the last 12 month period."
          }
        ]
      },
      {
        "abstract": false,
        "code": "269",
        "display": "For the treatment of acne vulgaris.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "For the treatment of acne vulgaris."
          }
        ]
      },
      {
        "abstract": false,
        "code": "270",
        "display": "Limited to 2 weeks supply for acute pain.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "Limited to 2 weeks supply for acute pain."
          }
        ]
      },
      {
        "abstract": false,
        "code": "273",
        "display": "For the treatment of primary biliary cirrhosis.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "For the treatment of primary biliary cirrhosis."
          }
        ]
      },
      {
        "abstract": false,
        "code": "274",
        "display": "For the treatment of oral/esophageal candidiasis in immunocompromised patients (e.g. patients with malignancies and transplant patients) who have failed to respond to nystatin or imidazoles and when oral tablets of fluconazole cannot be tolerated.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "For the treatment of oral/esophageal candidiasis in immunocompromised patients (e.g. patients with malignancies and transplant patients) who have failed to respond to nystatin or imidazoles and when oral tablets of fluconazole cannot be tolerated."
          }
        ]
      },
      {
        "abstract": false,
        "code": "275",
        "display": "For the treatment of patients with disseminated candidiasis when oral tablets of fluconazole cannot be tolerated.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "For the treatment of patients with disseminated candidiasis when oral tablets of fluconazole cannot be tolerated."
          }
        ]
      },
      {
        "abstract": false,
        "code": "276",
        "display": "For the treatment of patients with cryptococcal meningitis when oral tablets of fluconazole cannot be tolerated.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "For the treatment of patients with cryptococcal meningitis when oral tablets of fluconazole cannot be tolerated."
          }
        ]
      },
      {
        "abstract": false,
        "code": "277",
        "display": "For the treatment of patients with vulvovaginal candidiasis when oral tablets of fluconazole cannot be tolerated.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "For the treatment of patients with vulvovaginal candidiasis when oral tablets of fluconazole cannot be tolerated."
          }
        ]
      },
      {
        "abstract": false,
        "code": "280",
        "display": "For the control and prophylaxis of hypercalcemia of malignancy.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "For the control and prophylaxis of hypercalcemia of malignancy."
          }
        ]
      },
      {
        "abstract": false,
        "code": "290",
        "display": "For patients with urinary frequency, urgency or urge incontinence who have: Failed to respond to behavioral techniques AND an adequate trial of oxybutynin with gradual dose escalation has shown to be either ineffective or resulted in unacceptable side effects.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "For patients with urinary frequency, urgency or urge incontinence who have: Failed to respond to behavioral techniques AND an adequate trial of oxybutynin with gradual dose escalation has shown to be either ineffective or resulted in unacceptable side effects."
          }
        ]
      },
      {
        "abstract": false,
        "code": "293",
        "display": "Gastroesophageal Reflux Disease (GERD) For the treatment of erosive GERD or upper GI malignancy; OR For the treatment of non-erosive GERD after failure of H2-receptor antagonist therapy.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "Gastroesophageal Reflux Disease (GERD) For the treatment of erosive GERD or upper GI malignancy; OR For the treatment of non-erosive GERD after failure of H2-receptor antagonist therapy."
          }
        ]
      },
      {
        "abstract": false,
        "code": "295",
        "display": "H. pylori-positive Peptic Ulcers: For the treatment of H. pylori-positive peptic ulcers where H. pylori is documented, by serology, urea breath test or endoscopy, for a one-week course in combination with antimicrobial therapy.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "H. pylori-positive Peptic Ulcers: For the treatment of H. pylori-positive peptic ulcers where H. pylori is documented, by serology, urea breath test or endoscopy, for a one-week course in combination with antimicrobial therapy."
          }
        ]
      },
      {
        "abstract": false,
        "code": "297",
        "display": "Confirmed Peptic Ulcers or NSAID-induced Ulcer Prophylaxis: For the treatment of confirmed peptic ulcers and NSAID-induced ulcers; OR For the prophylaxis of NSAID-induced ulcers for patients at increased risk of GI bleeding.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "Confirmed Peptic Ulcers or NSAID-induced Ulcer Prophylaxis: For the treatment of confirmed peptic ulcers and NSAID-induced ulcers; OR For the prophylaxis of NSAID-induced ulcers for patients at increased risk of GI bleeding."
          }
        ]
      },
      {
        "abstract": false,
        "code": "306",
        "display": "a) For the treatment of H. pylori-positive peptic ulcers where H. pylori is documented, by serology, breath test or endoscopy, for a one week course.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "a) For the treatment of H. pylori-positive peptic ulcers where H. pylori is documented, by serology, breath test or endoscopy, for a one week course."
          }
        ]
      },
      {
        "abstract": false,
        "code": "307",
        "display": "b) For the retreatment of H. pylori-positive peptic ulcers where H. pylori recurrence or persistence is documented, by breath test or endoscopy, for a one week course.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "b) For the retreatment of H. pylori-positive peptic ulcers where H. pylori recurrence or persistence is documented, by breath test or endoscopy, for a one week course."
          }
        ]
      },
      {
        "abstract": false,
        "code": "310",
        "display": "As second-line therapy for patients who do not have an adequate intraocular pressure lowering response to monotherapy with ophthalmic beta-blocking agents.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "As second-line therapy for patients who do not have an adequate intraocular pressure lowering response to monotherapy with ophthalmic beta-blocking agents."
          }
        ]
      },
      {
        "abstract": false,
        "code": "311",
        "display": "For the treatment of patients who have failed on a less costly listed alternative.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "For the treatment of patients who have failed on a less costly listed alternative."
          }
        ]
      },
      {
        "abstract": false,
        "code": "315",
        "display": "For the treatment of depression.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "For the treatment of depression."
          }
        ]
      },
      {
        "abstract": false,
        "code": "316",
        "display": "For patients who have failed an adequate trial of acetaminophen (e.g. acetaminophen 1g QID for several weeks) and have had:",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "For patients who have failed an adequate trial of acetaminophen (e.g. acetaminophen 1g QID for several weeks) and have had:"
          }
        ]
      },
      {
        "abstract": false,
        "code": "317",
        "display": "For patients who have had:",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "For patients who have had:"
          }
        ]
      },
      {
        "abstract": false,
        "code": "319",
        "display": "For the treatment of Paget's disease.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "For the treatment of Paget's disease."
          }
        ]
      },
      {
        "abstract": false,
        "code": "320",
        "display": "For patients with recurrent or progressive glioblastoma multiforme or anaplastic astrocytoma.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "For patients with recurrent or progressive glioblastoma multiforme or anaplastic astrocytoma."
          }
        ]
      },
      {
        "abstract": false,
        "code": "321",
        "display": "In children age 16 and under, as adjunctive therapy in the treatment of seizure disorders where control by other listed anticonvulsants has been unsatisfactory.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "In children age 16 and under, as adjunctive therapy in the treatment of seizure disorders where control by other listed anticonvulsants has been unsatisfactory."
          }
        ]
      },
      {
        "abstract": false,
        "code": "323",
        "display": "For the acute treatment of pulmonary embolism, maximum of three weeks.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "For the acute treatment of pulmonary embolism, maximum of three weeks."
          }
        ]
      },
      {
        "abstract": false,
        "code": "326",
        "display": "For the treatment of emesis in patients receiving radiation therapy which consists of single fraction treatment to the abdominal cavity, hemi-body irradiation and total body irradiation.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "For the treatment of emesis in patients receiving radiation therapy which consists of single fraction treatment to the abdominal cavity, hemi-body irradiation and total body irradiation."
          }
        ]
      },
      {
        "abstract": false,
        "code": "330",
        "display": "For the treatment of asthma in patients who are using optimum anti-inflammatory treatment and are still experiencing breakthrough symptoms.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "For the treatment of asthma in patients who are using optimum anti-inflammatory treatment and are still experiencing breakthrough symptoms."
          }
        ]
      },
      {
        "abstract": false,
        "code": "332",
        "display": "SST/BJ (Gram negative bacteria): Skin/soft tissue and bone/joint infection due to gram negative bacteria; severe diabetic foot infection; severe otitis externa; decubitus ulcers.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "SST/BJ (Gram negative bacteria): Skin/soft tissue and bone/joint infection due to gram negative bacteria; severe diabetic foot infection; severe otitis externa; decubitus ulcers."
          }
        ]
      },
      {
        "abstract": false,
        "code": "333",
        "display": "GU Tract: Urinary tract infection/prostatitis/epididymitis caused by (suspected or documented) Pseudomonas; sexually transmitted diseases.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "GU Tract: Urinary tract infection/prostatitis/epididymitis caused by (suspected or documented) Pseudomonas; sexually transmitted diseases."
          }
        ]
      },
      {
        "abstract": false,
        "code": "334",
        "display": "COPD with risk: Acute bacterial exacerbation of chronic obstructive pulmonary disease (COPD) with risk factors; bronchiectasis; pneumonic illness with cystic fibrosis.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "COPD with risk: Acute bacterial exacerbation of chronic obstructive pulmonary disease (COPD) with risk factors; bronchiectasis; pneumonic illness with cystic fibrosis."
          }
        ]
      },
      {
        "abstract": false,
        "code": "336",
        "display": "Step-Down: Step-down therapy after parenteral therapy or hospital/emergency department discharge; febrile neutropenia.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "Step-Down: Step-down therapy after parenteral therapy or hospital/emergency department discharge; febrile neutropenia."
          }
        ]
      },
      {
        "abstract": false,
        "code": "337",
        "display": "CAP with co-morbidity: Community acquired pneumonia with co-morbid illnesses or failure to first-line therapy.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "CAP with co-morbidity: Community acquired pneumonia with co-morbid illnesses or failure to first-line therapy."
          }
        ]
      },
      {
        "abstract": false,
        "code": "338",
        "display": "COPD with risk: Acute bacterial exacerbation of chronic obstructive pulmonary disease (COPD) with risk factors; bronchiectasis.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "COPD with risk: Acute bacterial exacerbation of chronic obstructive pulmonary disease (COPD) with risk factors; bronchiectasis."
          }
        ]
      },
      {
        "abstract": false,
        "code": "339",
        "display": "Step-Down: Step-down therapy after parenteral therapy or hospital / emergency department discharge.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "Step-Down: Step-down therapy after parenteral therapy or hospital / emergency department discharge."
          }
        ]
      },
      {
        "abstract": false,
        "code": "346",
        "display": "For the first-line treatment of patients with metastatic colorectal cancer in whom combination chemotherapy is not recommended.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "For the first-line treatment of patients with metastatic colorectal cancer in whom combination chemotherapy is not recommended."
          }
        ]
      },
      {
        "abstract": false,
        "code": "347",
        "display": "Initial Trial: For patients with mild to moderate Alzheimer's Disease (Mini-Mental State Exam [MMSE] 10-26). Patients will be reimbursed for a period of up to 3 months after which continued treatment must be reassessed.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "Initial Trial: For patients with mild to moderate Alzheimer's Disease (Mini-Mental State Exam [MMSE] 10-26). Patients will be reimbursed for a period of up to 3 months after which continued treatment must be reassessed."
          }
        ]
      },
      {
        "abstract": false,
        "code": "348",
        "display": "Continuation: Further reimbursement will be made available to those patients whose disease has not progressed/deteriorated while on this drug. Patients must continue to have a MMSE score of 10-26.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "Continuation: Further reimbursement will be made available to those patients whose disease has not progressed/deteriorated while on this drug. Patients must continue to have a MMSE score of 10-26."
          }
        ]
      },
      {
        "abstract": false,
        "code": "349",
        "display": "For the secondary prevention of stroke.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "For the secondary prevention of stroke."
          }
        ]
      },
      {
        "abstract": false,
        "code": "350",
        "display": "GI: Traveller's diarrhea; enteric fever syndromes; Crohn's disease.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "GI: Traveller's diarrhea; enteric fever syndromes; Crohn's disease."
          }
        ]
      },
      {
        "abstract": false,
        "code": "351",
        "display": "For the management of benign prostatic hyperplasia where six weeks of treatment with other formulary alpha blockers (e.g. doxazosin, terazosin, tamsulosin) have been ineffective.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "For the management of benign prostatic hyperplasia where six weeks of treatment with other formulary alpha blockers (e.g. doxazosin, terazosin, tamsulosin) have been ineffective."
          }
        ]
      },
      {
        "abstract": false,
        "code": "352",
        "display": "For the management of benign prostatic hyperplasia where other formulary alpha blockers (e.g. doxazosin, terazosin, tamsulosin) have produced intolerable side effects.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "For the management of benign prostatic hyperplasia where other formulary alpha blockers (e.g. doxazosin, terazosin, tamsulosin) have produced intolerable side effects."
          }
        ]
      },
      {
        "abstract": false,
        "code": "353",
        "display": "For the prophylaxis or treatment of B. anthracis exposure.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "For the prophylaxis or treatment of B. anthracis exposure."
          }
        ]
      },
      {
        "abstract": false,
        "code": "358",
        "display": "For the treatment of bony metastases in patients with breast cancer.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "For the treatment of bony metastases in patients with breast cancer."
          }
        ]
      },
      {
        "abstract": false,
        "code": "359",
        "display": "For the prevention and treatment of osteolytic lesions in patients with multiple myeloma.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "For the prevention and treatment of osteolytic lesions in patients with multiple myeloma."
          }
        ]
      },
      {
        "abstract": false,
        "code": "360",
        "display": "For the treatment of metastatic breast cancer where patients have progressed after prior chemotherapy.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "For the treatment of metastatic breast cancer where patients have progressed after prior chemotherapy."
          }
        ]
      },
      {
        "abstract": false,
        "code": "362",
        "display": "Methicillin-resistant Staphylococcus species (MRSA, MRSE) infections in patients who are intolerant or have failed vancomycin therapy, or have contraindications to venous access.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "Methicillin-resistant Staphylococcus species (MRSA, MRSE) infections in patients who are intolerant or have failed vancomycin therapy, or have contraindications to venous access."
          }
        ]
      },
      {
        "abstract": false,
        "code": "363",
        "display": "Vancomycin resistant Enterococcus species (VRE) infections in patients switching from IV linezolid.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "Vancomycin resistant Enterococcus species (VRE) infections in patients switching from IV linezolid."
          }
        ]
      },
      {
        "abstract": false,
        "code": "364",
        "display": "Step-down therapy for the treatment of methicillin-resistant Staphylococcus species or vancomycin resistant Enterococcus species (VRE) infections after parenteral therapy or hospital/ emergency department discharge.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "Step-down therapy for the treatment of methicillin-resistant Staphylococcus species or vancomycin resistant Enterococcus species (VRE) infections after parenteral therapy or hospital/ emergency department discharge."
          }
        ]
      },
      {
        "abstract": false,
        "code": "365",
        "display": "For the treatment of metastatic breast cancer in hormone receptor positive post-menopausal women.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "For the treatment of metastatic breast cancer in hormone receptor positive post-menopausal women."
          }
        ]
      },
      {
        "abstract": false,
        "code": "365",
        "display": "For the treatment of metastatic breast cancer in hormone receptor positive post-menopausal women.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "For the treatment of metastatic breast cancer in hormone receptor positive post-menopausal women."
          }
        ]
      },
      {
        "abstract": false,
        "code": "367",
        "display": "For the treatment of patients with Parkinson's disease with 25% of the waking day in the off state despite maximally tolerated doses of levodopa.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "For the treatment of patients with Parkinson's disease with 25% of the waking day in the off state despite maximally tolerated doses of levodopa."
          }
        ]
      },
      {
        "abstract": false,
        "code": "371",
        "display": "For the prophylaxis (max: 75mg daily) of institutionalized individuals during confirmed outbreaks of Influenza A or Influenza B.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "For the prophylaxis (max: 75mg daily) of institutionalized individuals during confirmed outbreaks of Influenza A or Influenza B."
          }
        ]
      },
      {
        "abstract": false,
        "code": "372",
        "display": "For the treatment (max: 75mg bid) of institutionalized individuals during confirmed outbreaks due to: Influenza B or, Influenza A (as an alternative to amantadine) or, Influenza A where new cases have developed despite amantadine prophylaxis.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "For the treatment (max: 75mg bid) of institutionalized individuals during confirmed outbreaks due to: Influenza B or, Influenza A (as an alternative to amantadine) or, Influenza A where new cases have developed despite amantadine prophylaxis."
          }
        ]
      },
      {
        "abstract": false,
        "code": "373",
        "display": "Failed or, experienced intractable side effects, or have a contraindication to, alendronate OR risedronate.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "Failed or, experienced intractable side effects, or have a contraindication to, alendronate OR risedronate."
          }
        ]
      },
      {
        "abstract": false,
        "code": "374",
        "display": "For the treatment of CMV retinitis in patients with AIDS.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "For the treatment of CMV retinitis in patients with AIDS."
          }
        ]
      },
      {
        "abstract": false,
        "code": "378",
        "display": "For the post-operative prophylaxis of venous thromboembolic events in patients undergoing orthopedic surgery of the lower limbs such as hip fracture, hip replacement or knee surgery.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "For the post-operative prophylaxis of venous thromboembolic events in patients undergoing orthopedic surgery of the lower limbs such as hip fracture, hip replacement or knee surgery."
          }
        ]
      },
      {
        "abstract": false,
        "code": "379",
        "display": "For second line therapy of patients with chronic lymphocytic leukemia (CLL) who have failed or are intolerant to chlorambucil.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "For second line therapy of patients with chronic lymphocytic leukemia (CLL) who have failed or are intolerant to chlorambucil."
          }
        ]
      },
      {
        "abstract": false,
        "code": "380",
        "display": "For use in combination with a HMG-CoA reductase inhibitor ('statin') in patients with hypercholesterolemia who have not reached target LDL levels despite the use of maximally tolerated doses.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "For use in combination with a HMG-CoA reductase inhibitor ('statin') in patients with hypercholesterolemia who have not reached target LDL levels despite the use of maximally tolerated doses."
          }
        ]
      },
      {
        "abstract": false,
        "code": "381",
        "display": "For use as monotherapy in the management of hypercholesterolemia in patients who are intolerant to HMG-CoA reductase inhibitors or where HMG-CoA reductase inhibitors are contraindicated.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "For use as monotherapy in the management of hypercholesterolemia in patients who are intolerant to HMG-CoA reductase inhibitors or where HMG-CoA reductase inhibitors are contraindicated."
          }
        ]
      },
      {
        "abstract": false,
        "code": "382",
        "display": "For the treatment of asthma in patients aged 2-5 years old.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "For the treatment of asthma in patients aged 2-5 years old."
          }
        ]
      },
      {
        "abstract": false,
        "code": "383",
        "display": "For use in combination with moisturizers or oral antihistamines in patients with atopic dermatitis who have failed or are intolerant to an 8 week trial of an intermediate potency topical steroid.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "For use in combination with moisturizers or oral antihistamines in patients with atopic dermatitis who have failed or are intolerant to an 8 week trial of an intermediate potency topical steroid."
          }
        ]
      },
      {
        "abstract": false,
        "code": "384",
        "display": "For use in combination with an alpha blocker for the treatment of men with symptomatic Benign Prostatic Hyperplasia.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "For use in combination with an alpha blocker for the treatment of men with symptomatic Benign Prostatic Hyperplasia."
          }
        ]
      },
      {
        "abstract": false,
        "code": "385",
        "display": "For monotherapy, as a second line agent in patients with symptomatic Benign Prostatic Hyperplasia following treatment failure or intolerance to an alpha blocker.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "For monotherapy, as a second line agent in patients with symptomatic Benign Prostatic Hyperplasia following treatment failure or intolerance to an alpha blocker."
          }
        ]
      },
      {
        "abstract": false,
        "code": "386",
        "display": "For the treatment of primary sclerosing cholangitis.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "For the treatment of primary sclerosing cholangitis."
          }
        ]
      },
      {
        "abstract": false,
        "code": "387",
        "display": "For use as adjunctive therapy with an ophthalmic beta-blocking agent in an urgent situation (e.g. patients with a high baseline intraocular pressure) where monotherapy is unlikely to be effective.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "For use as adjunctive therapy with an ophthalmic beta-blocking agent in an urgent situation (e.g. patients with a high baseline intraocular pressure) where monotherapy is unlikely to be effective."
          }
        ]
      },
      {
        "abstract": false,
        "code": "388",
        "display": "For the treatment of patients with Type 1 diabetes mellitus.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "For the treatment of patients with Type 1 diabetes mellitus."
          }
        ]
      },
      {
        "abstract": false,
        "code": "389",
        "display": "For the treatment of patients with Type 2 diabetes mellitus using insulin in an intensive regimen with 3 or more injections per day or an insulin pump.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "For the treatment of patients with Type 2 diabetes mellitus using insulin in an intensive regimen with 3 or more injections per day or an insulin pump."
          }
        ]
      },
      {
        "abstract": false,
        "code": "390",
        "display": "For the treatment of patients with Type 2 diabetes mellitus who are either experiencing recurrent hypoglycemia OR are unable to achieve adequate post-prandial glucose control while on a less intensive regimen of regular insulin (1-2 injections per day).",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "For the treatment of patients with Type 2 diabetes mellitus who are either experiencing recurrent hypoglycemia OR are unable to achieve adequate post-prandial glucose control while on a less intensive regimen of regular insulin (1-2 injections per day)."
          }
        ]
      },
      {
        "abstract": false,
        "code": "391",
        "display": "For patients with moderate to severe COPD with persistent respiratory symptoms despite an adequate trial of, or an intolerance to, a regularly scheduled short-acting bronchodilator AND a long-acting anticholinergic.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "For patients with moderate to severe COPD with persistent respiratory symptoms despite an adequate trial of, or an intolerance to, a regularly scheduled short-acting bronchodilator AND a long-acting anticholinergic."
          }
        ]
      },
      {
        "abstract": false,
        "code": "392",
        "display": "For the prophylaxis of organ rejection in patients receiving allogeneic renal transplants.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "For the prophylaxis of organ rejection in patients receiving allogeneic renal transplants."
          }
        ]
      },
      {
        "abstract": false,
        "code": "393",
        "display": "For use as initial therapy in an urgent situation (e.g. patients with a high baseline intraocular pressure) where monotherapy is unlikely to be effective.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "For use as initial therapy in an urgent situation (e.g. patients with a high baseline intraocular pressure) where monotherapy is unlikely to be effective."
          }
        ]
      },
      {
        "abstract": false,
        "code": "394",
        "display": "For patients with uncomplicated urinary tract infections (acute cystitis) who have failure, intolerance or hypersensitivity to all formulary antibiotic alternatives that are listed as General Benefits.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "For patients with uncomplicated urinary tract infections (acute cystitis) who have failure, intolerance or hypersensitivity to all formulary antibiotic alternatives that are listed as General Benefits."
          }
        ]
      },
      {
        "abstract": false,
        "code": "395",
        "display": "For patients with complicated urinary tract infections or acute uncomplicated pyelonephritis who have failure, intolerance or hypersensitivity to all formulary antibiotic alternatives that are listed as General Benefits.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "For patients with complicated urinary tract infections or acute uncomplicated pyelonephritis who have failure, intolerance or hypersensitivity to all formulary antibiotic alternatives that are listed as General Benefits."
          }
        ]
      },
      {
        "abstract": false,
        "code": "396",
        "display": "As an alternative to tamoxifen for the adjuvant treatment of postmenopausal women with hormone receptor positive breast cancer.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "As an alternative to tamoxifen for the adjuvant treatment of postmenopausal women with hormone receptor positive breast cancer."
          }
        ]
      },
      {
        "abstract": false,
        "code": "397",
        "display": "For male patients with confirmed low morning serum testosterone levels associated with documented, symptomatic hypothalamic, pituitary or testicular disease, or in HIV-infected patients.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "For male patients with confirmed low morning serum testosterone levels associated with documented, symptomatic hypothalamic, pituitary or testicular disease, or in HIV-infected patients."
          }
        ]
      },
      {
        "abstract": false,
        "code": "398",
        "display": "For short-term use in women who are experiencing symptoms of menopause.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "For short-term use in women who are experiencing symptoms of menopause."
          }
        ]
      },
      {
        "abstract": false,
        "code": "399",
        "display": "Outpatient continuation of treatment for documented invasive aspergillosis in patients who have demonstrated a clinical response to either oral or parenteral voriconazole.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "Outpatient continuation of treatment for documented invasive aspergillosis in patients who have demonstrated a clinical response to either oral or parenteral voriconazole."
          }
        ]
      },
      {
        "abstract": false,
        "code": "400",
        "display": "For the treatment of essential thrombocytosis in patients who are intolerant of or who have failed hydroxyurea therapy.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "For the treatment of essential thrombocytosis in patients who are intolerant of or who have failed hydroxyurea therapy."
          }
        ]
      },
      {
        "abstract": false,
        "code": "401",
        "display": "Other Gastrointestinal Disorders: For the treatment of gastroduodenal Crohns disease, short-gut syndrome, scleroderma, or pancreatitis.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "Other Gastrointestinal Disorders: For the treatment of gastroduodenal Crohns disease, short-gut syndrome, scleroderma, or pancreatitis."
          }
        ]
      },
      {
        "abstract": false,
        "code": "402",
        "display": "Severe Conditions: For the treatment of severe esophagitis, Zollinger-Ellison syndrome, esophageal stricture, persistent symptoms of GERD or persistent erosive esophagitis, or upon hospital discharge following a gastrointestinal bleed.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "Severe Conditions: For the treatment of severe esophagitis, Zollinger-Ellison syndrome, esophageal stricture, persistent symptoms of GERD or persistent erosive esophagitis, or upon hospital discharge following a gastrointestinal bleed."
          }
        ]
      },
      {
        "abstract": false,
        "code": "403",
        "display": "For the treatment of hormone receptor positive early breast cancer in postmenopausal women who have received 5 years of adjuvant tamoxifen therapy.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "For the treatment of hormone receptor positive early breast cancer in postmenopausal women who have received 5 years of adjuvant tamoxifen therapy."
          }
        ]
      },
      {
        "abstract": false,
        "code": "405",
        "display": "For the treatment of hyperprolactinemia in patients who have: Failed to respond to a greater than or equal to 3 month trial of bromocriptine; or Failed to tolerate bromocriptine; or Failed to shrink a prolactinoma by greater than 1 cm after 12 months of bromocriptine therapy",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "For the treatment of hyperprolactinemia in patients who have: Failed to respond to a greater than or equal to 3 month trial of bromocriptine; or Failed to tolerate bromocriptine; or Failed to shrink a prolactinoma by greater than 1 cm after 12 months of bromocriptine therapy"
          }
        ]
      },
      {
        "abstract": false,
        "code": "406",
        "display": "For adjuvant treatment of stage 3 or high risk stage 2 colon cancer in patients who have completed surgery (within three months), who would normally be candidates for adjuvant chemotherapy with 5FU/LV.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "For adjuvant treatment of stage 3 or high risk stage 2 colon cancer in patients who have completed surgery (within three months), who would normally be candidates for adjuvant chemotherapy with 5FU/LV."
          }
        ]
      },
      {
        "abstract": false,
        "code": "407",
        "display": "For the sequential treatment of postmenopausal women with estrogen receptor-positive early breast cancer who have received 2-3 years of initial adjuvant tamoxifen therapy.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "For the sequential treatment of postmenopausal women with estrogen receptor-positive early breast cancer who have received 2-3 years of initial adjuvant tamoxifen therapy."
          }
        ]
      },
      {
        "abstract": false,
        "code": "408",
        "display": "As an alternative to tamoxifen for the adjuvant treatment of post-menopausal women with hormone receptor positive early breast cancer for a maximum of five years.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "As an alternative to tamoxifen for the adjuvant treatment of post-menopausal women with hormone receptor positive early breast cancer for a maximum of five years."
          }
        ]
      },
      {
        "abstract": false,
        "code": "409",
        "display": "As part of the CAPOX regimen for the first-line and second-line treatment of metastatic colorectal cancer",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "As part of the CAPOX regimen for the first-line and second-line treatment of metastatic colorectal cancer"
          }
        ]
      },
      {
        "abstract": false,
        "code": "410",
        "display": "For prophylaxis of organ rejection in adult patients receiving allogeneic kidney transplants",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "For prophylaxis of organ rejection in adult patients receiving allogeneic kidney transplants"
          }
        ]
      },
      {
        "abstract": false,
        "code": "412",
        "display": "For the management of focal spasticity, due to stroke or spinal cord injury in adults.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "For the management of focal spasticity, due to stroke or spinal cord injury in adults."
          }
        ]
      },
      {
        "abstract": false,
        "code": "413",
        "display": "For the treatment of focal spasticity secondary to cerebral palsy in patients two years of age or older.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "For the treatment of focal spasticity secondary to cerebral palsy in patients two years of age or older."
          }
        ]
      },
      {
        "abstract": false,
        "code": "414",
        "display": "For treatment: 2 inhalations of 5mg (10mg) bid for 5 days,",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "For treatment: 2 inhalations of 5mg (10mg) bid for 5 days,"
          }
        ]
      },
      {
        "abstract": false,
        "code": "415",
        "display": "For prophylaxis: 2 inhalations of 5mg (10mg) once daily for 10 days.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "For prophylaxis: 2 inhalations of 5mg (10mg) once daily for 10 days."
          }
        ]
      },
      {
        "abstract": false,
        "code": "417",
        "display": "For the treatment of severe plaque psoriasis in patients 18 years of age or older who have experienced failure, intolerance, or have a contraindication to adequate trials of several standard therapies.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "For the treatment of severe plaque psoriasis in patients 18 years of age or older who have experienced failure, intolerance, or have a contraindication to adequate trials of several standard therapies."
          }
        ]
      },
      {
        "abstract": false,
        "code": "418",
        "display": "For the treatment of severe plaque psoriasis in patients 18 years of age or older who have experienced failure, intolerance, or have a contraindication to adequate trials of several standard therapies.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "For the treatment of severe plaque psoriasis in patients 18 years of age or older who have experienced failure, intolerance, or have a contraindication to adequate trials of several standard therapies."
          }
        ]
      },
      {
        "abstract": false,
        "code": "419",
        "display": "For the treatment of severe plaque psoriasis in patients 18 years of age or older who have experienced failure, intolerance, or have a contraindication to adequate trials of several standard therapies.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "For the treatment of severe plaque psoriasis in patients 18 years of age or older who have experienced failure, intolerance, or have a contraindication to adequate trials of several standard therapies."
          }
        ]
      },
      {
        "abstract": false,
        "code": "420",
        "display": "ESAs (Eprex or Aranesp) for patients with: Cancer diagnosis and receiving chemotherapy; AND Presence of anemia caused by chemotherapy with a hemoglobin count less than 100g/L; AND Patient has been informed of the risks and benefits of ESA therapy AND Anemia cannot be managed by use of blood transfusions due to at least one of the following: Religious beliefs do not allow the patient to receive transfusions; Previous severe (potentially life-threatening) reaction to a transfusion or difficulty cross-matching; Myeloid cancers that cannot be managed with blood transfusions; Patient lives far away from treatment centre and/or transfusions cannot be coordinated with chemotherapy; Patients receiving neoadjuvant chemotherapy with anemia and at risk of high blood losses due to surgery",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "ESAs (Eprex or Aranesp) for patients with: Cancer diagnosis and receiving chemotherapy; AND Presence of anemia caused by chemotherapy with a hemoglobin count less than 100g/L; AND Patient has been informed of the risks and benefits of ESA therapy AND Anemia cannot be managed by use of blood transfusions due to at least one of the following: Religious beliefs do not allow the patient to receive transfusions; Previous severe (potentially life-threatening) reaction to a transfusion or difficulty cross-matching; Myeloid cancers that cannot be managed with blood transfusions; Patient lives far away from treatment centre and/or transfusions cannot be coordinated with chemotherapy; Patients receiving neoadjuvant chemotherapy with anemia and at risk of high blood losses due to surgery"
          }
        ]
      },
      {
        "abstract": false,
        "code": "421",
        "display": "For the treatment of blepharospasm associated with dystonia, including benign essential blepharospasm or VII nerve disorders in adults.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "For the treatment of blepharospasm associated with dystonia, including benign essential blepharospasm or VII nerve disorders in adults."
          }
        ]
      },
      {
        "abstract": false,
        "code": "422",
        "display": "For the treatment of patients with neovascular (wet) age-related macular degeneration (AMD) in a verteporfin PDT (Visudyne)-naive eye.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "For the treatment of patients with neovascular (wet) age-related macular degeneration (AMD) in a verteporfin PDT (Visudyne)-naive eye."
          }
        ]
      },
      {
        "abstract": false,
        "code": "423",
        "display": "For smoking-cessation treatment in adults, in conjunction with smoking-cessation counseling.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "For smoking-cessation treatment in adults, in conjunction with smoking-cessation counseling."
          }
        ]
      },
      {
        "abstract": false,
        "code": "424",
        "display": "For the first-line treatment of chronic lymphocytic leukemia (CLL) in combination with rituximab (with or without cyclophosphamide).",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "For the first-line treatment of chronic lymphocytic leukemia (CLL) in combination with rituximab (with or without cyclophosphamide)."
          }
        ]
      },
      {
        "abstract": false,
        "code": "425",
        "display": "For the treatment of newly diagnosed glioblastoma multiforme.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "For the treatment of newly diagnosed glioblastoma multiforme."
          }
        ]
      },
      {
        "abstract": false,
        "code": "426",
        "display": "In combination with trastuzumab and cisplatin for the treatment of patients with HER2-positive metastatic adenocarcinoma of the stomach or gastro-esophageal junction who have not received prior anti-cancer treatment for their metastatic disease.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "In combination with trastuzumab and cisplatin for the treatment of patients with HER2-positive metastatic adenocarcinoma of the stomach or gastro-esophageal junction who have not received prior anti-cancer treatment for their metastatic disease."
          }
        ]
      },
      {
        "abstract": false,
        "code": "427",
        "display": "For the neo-adjuvant treatment of rectal cancer.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "For the neo-adjuvant treatment of rectal cancer."
          }
        ]
      },
      {
        "abstract": false,
        "code": "428",
        "display": "For the treatment of osteoporosis in postmenopausal women who have experienced a further significant decline in BMD after 1 year continuous bisphosphonate therapy and meet at least two of the following criteria: Age greater than 75 years old; A bone mineral density (BMD) T-score less than or equal to -2.5; Prior fragility fracture",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "For the treatment of osteoporosis in postmenopausal women who have experienced a further significant decline in BMD after 1 year continuous bisphosphonate therapy and meet at least two of the following criteria: Age greater than 75 years old; A bone mineral density (BMD) T-score less than or equal to -2.5; Prior fragility fracture"
          }
        ]
      },
      {
        "abstract": false,
        "code": "429",
        "display": "For the treatment of osteoporosis in postmenopausal women who would otherwise be eligible for funding for oral bisphosphonates, but for whom bisphosphonates are contraindicated due to hypersensitivity or abnormalities of the esophagus (e.g., esophageal stricture or achalasia), AND have at least two of the following: Age greater than 75 years old; A prior fragility fracture; A bone mineral density (BMD) T-score less than or equal to -2.5",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "For the treatment of osteoporosis in postmenopausal women who would otherwise be eligible for funding for oral bisphosphonates, but for whom bisphosphonates are contraindicated due to hypersensitivity or abnormalities of the esophagus (e.g., esophageal stricture or achalasia), AND have at least two of the following: Age greater than 75 years old; A prior fragility fracture; A bone mineral density (BMD) T-score less than or equal to -2.5"
          }
        ]
      },
      {
        "abstract": false,
        "code": "430",
        "display": "As adjunctive therapy in the treatment of adult patients with partial onset seizures who have had an inadequate response or have significant intolerance to at least 3 less costly anticonvulsant therapies; AND Patients are under the care of a physician experienced in the treatment of epilepsy.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "As adjunctive therapy in the treatment of adult patients with partial onset seizures who have had an inadequate response or have significant intolerance to at least 3 less costly anticonvulsant therapies; AND Patients are under the care of a physician experienced in the treatment of epilepsy."
          }
        ]
      },
      {
        "abstract": false,
        "code": "431",
        "display": "For the prevention of stroke and systemic embolism in at risk patients with non-valvular atrial fibrillation (AF), AND in whom: Anticoagulation is inadequate following a reasonable trial on warfarin; OR Anticoagulation with warfarin is contraindicated or not possible due to inability to regularly monitor via International Normalized Ratio (INR); testing (i.e., no access to INR testing services at a laboratory, clinic; pharmacy, and at home).",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "For the prevention of stroke and systemic embolism in at risk patients with non-valvular atrial fibrillation (AF), AND in whom: Anticoagulation is inadequate following a reasonable trial on warfarin; OR Anticoagulation with warfarin is contraindicated or not possible due to inability to regularly monitor via International Normalized Ratio (INR); testing (i.e., no access to INR testing services at a laboratory, clinic; pharmacy, and at home)."
          }
        ]
      },
      {
        "abstract": false,
        "code": "432",
        "display": "For the management of pelvic pain associated with endometriosis in patients for whom one or more less costly options are either ineffective or cannot be used.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "For the management of pelvic pain associated with endometriosis in patients for whom one or more less costly options are either ineffective or cannot be used."
          }
        ]
      },
      {
        "abstract": false,
        "code": "433",
        "display": "For the prevention of venous thromboembolic events in patients who have undergone elective total knee replacement (TKR) surgery.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "For the prevention of venous thromboembolic events in patients who have undergone elective total knee replacement (TKR) surgery."
          }
        ]
      },
      {
        "abstract": false,
        "code": "434",
        "display": "For the prevention of venous thromboembolic events in patients who have undergone elective total hip replacement (THR).",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "For the prevention of venous thromboembolic events in patients who have undergone elective total hip replacement (THR)."
          }
        ]
      },
      {
        "abstract": false,
        "code": "435",
        "display": "For the prevention of stroke and systemic embolism in at-risk patients who have non-valvular atrial fibrillation (AF) AND in whom: Anticoagulation is inadequate following a reasonable trial on warfarin; OR Anticoagulation with warfarin is contraindicated or not possible due to inability to regularly monitor via International Normalized Ratio (INR); testing (i.e., no access to INR testing service at a laboratory, clinic; pharmacy, and at home).",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "For the prevention of stroke and systemic embolism in at-risk patients who have non-valvular atrial fibrillation (AF) AND in whom: Anticoagulation is inadequate following a reasonable trial on warfarin; OR Anticoagulation with warfarin is contraindicated or not possible due to inability to regularly monitor via International Normalized Ratio (INR); testing (i.e., no access to INR testing service at a laboratory, clinic; pharmacy, and at home)."
          }
        ]
      },
      {
        "abstract": false,
        "code": "436",
        "display": "For the treatment of osteoporosis in postmenopausal women who would otherwise be eligible for funding for oral bisphosphonates, but for whom bisphosphonates are contraindicated due to abnormalities of the esophagus (e.g. esophageal stricture or achalasia), AND have at least two of the following: Age greater than 75 years old; A prior fragility fracture; A bone mineral density (BMD) T-score less than or equal to -2.5",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "For the treatment of osteoporosis in postmenopausal women who would otherwise be eligible for funding for oral bisphosphonates, but for whom bisphosphonates are contraindicated due to abnormalities of the esophagus (e.g. esophageal stricture or achalasia), AND have at least two of the following: Age greater than 75 years old; A prior fragility fracture; A bone mineral density (BMD) T-score less than or equal to -2.5"
          }
        ]
      },
      {
        "abstract": false,
        "code": "437",
        "display": "For the treatment of opioid dependence in patients who have failed, have significant intolerance, have a contraindication to, or who are at high risk for toxicity with methadone.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "For the treatment of opioid dependence in patients who have failed, have significant intolerance, have a contraindication to, or who are at high risk for toxicity with methadone."
          }
        ]
      },
      {
        "abstract": false,
        "code": "438",
        "display": "For the treatment of opioid dependence when a methadone maintenance program is not available or accessible (i.e. No methadone maintenance programs available in the area, or waiting list is 3 months or longer).",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "For the treatment of opioid dependence when a methadone maintenance program is not available or accessible (i.e. No methadone maintenance programs available in the area, or waiting list is 3 months or longer)."
          }
        ]
      },
      {
        "abstract": false,
        "code": "439",
        "display": "For the treatment of patients with clinically significant diabetic macular edema (DME) for whom laser photocoagulation is also indicated; and a hemoglobin A1c of less than 11 percent.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "For the treatment of patients with clinically significant diabetic macular edema (DME) for whom laser photocoagulation is also indicated; and a hemoglobin A1c of less than 11 percent."
          }
        ]
      },
      {
        "abstract": false,
        "code": "440",
        "display": "For adult patients with urinary incontinence due to neurogenic detrusor overactivity resulting from neurogenic bladder associated with multiple sclerosis or subcervical spinal cord injury who fail to respond to behavioural medication and anticholinergics and/or are intolerant to anticholinergics.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "For adult patients with urinary incontinence due to neurogenic detrusor overactivity resulting from neurogenic bladder associated with multiple sclerosis or subcervical spinal cord injury who fail to respond to behavioural medication and anticholinergics and/or are intolerant to anticholinergics."
          }
        ]
      },
      {
        "abstract": false,
        "code": "441",
        "display": "In combination with ASA 75mg - 150mg daily for patients with acute coronary syndrome (i.e., ST elevation myocardial infarction [STEMI], non-ST elevation myocardial infarction [NSTEMI], or unstable angina [UA] with ONE of the following: Failure on optimal clopidogrel and ASA therapy as defined by definite stent thrombosis, or recurrent STEMI, or NSTEMI or UA after prior revascularization via percutaneous coronary intervention (PCI); OR STEMI and undergoing revascularization via PCI; OR NSTEMI or UA with high risk angiographic features and undergoing revascularization via PCI",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "In combination with ASA 75mg - 150mg daily for patients with acute coronary syndrome (i.e., ST elevation myocardial infarction [STEMI], non-ST elevation myocardial infarction [NSTEMI], or unstable angina [UA] with ONE of the following: Failure on optimal clopidogrel and ASA therapy as defined by definite stent thrombosis, or recurrent STEMI, or NSTEMI or UA after prior revascularization via percutaneous coronary intervention (PCI); OR STEMI and undergoing revascularization via PCI; OR NSTEMI or UA with high risk angiographic features and undergoing revascularization via PCI"
          }
        ]
      },
      {
        "abstract": false,
        "code": "442",
        "display": "For adult patients with severe chronic hand eczema AND unresponsive to an 8 week course of high potency topical corticosteroids.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "For adult patients with severe chronic hand eczema AND unresponsive to an 8 week course of high potency topical corticosteroids."
          }
        ]
      },
      {
        "abstract": false,
        "code": "443",
        "display": "For patients with moderate to severe COPD with persistent respiratory symptoms despite an adequate trial of, or an intolerance to, a regularly scheduled short-acting bronchodilator AND a long-acting anticholinergic.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "For patients with moderate to severe COPD with persistent respiratory symptoms despite an adequate trial of, or an intolerance to, a regularly scheduled short-acting bronchodilator AND a long-acting anticholinergic."
          }
        ]
      },
      {
        "abstract": false,
        "code": "444",
        "display": "For the treatment of deep vein thrombosis (DVT) or pulmonary embolism (PE) for up to six (6) months.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "For the treatment of deep vein thrombosis (DVT) or pulmonary embolism (PE) for up to six (6) months."
          }
        ]
      },
      {
        "abstract": false,
        "code": "445",
        "display": "For the treatment of patients with clinically significant macular edema secondary to branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO).",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "For the treatment of patients with clinically significant macular edema secondary to branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO)."
          }
        ]
      },
      {
        "abstract": false,
        "code": "446",
        "display": "Prophylaxis of febrile neutropenia for patients receiving chemotherapy with curative intent as follows: Primary G-CSF prophylaxis; OR Secondary G-CSF prophylaxis",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "Prophylaxis of febrile neutropenia for patients receiving chemotherapy with curative intent as follows: Primary G-CSF prophylaxis; OR Secondary G-CSF prophylaxis"
          }
        ]
      },
      {
        "abstract": false,
        "code": "447",
        "display": "Pre-Stem Cell Transplant Mobilization: For Peripheral Blood Progenitor Cell (PBPC) collection for peripheral stem cell transplant as treatment for malignant disease.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "Pre-Stem Cell Transplant Mobilization: For Peripheral Blood Progenitor Cell (PBPC) collection for peripheral stem cell transplant as treatment for malignant disease."
          }
        ]
      },
      {
        "abstract": false,
        "code": "448",
        "display": "At risk patients with non-valvular atrial fibrillation, for the prevention of stroke and systemic embolism AND in whom: Anticoagulation is inadequate following at least a 2-month trial on warfarin; OR Anticoagulation using warfarin is contraindicated or not possible due to inability to regularly monitor the patient via International Normalized Ratio (INR) testing (i.e. no access to INR testing services at a laboratory, clinic, pharmacy, and at home)",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "At risk patients with non-valvular atrial fibrillation, for the prevention of stroke and systemic embolism AND in whom: Anticoagulation is inadequate following at least a 2-month trial on warfarin; OR Anticoagulation using warfarin is contraindicated or not possible due to inability to regularly monitor the patient via International Normalized Ratio (INR) testing (i.e. no access to INR testing services at a laboratory, clinic, pharmacy, and at home)"
          }
        ]
      },
      {
        "abstract": false,
        "code": "449",
        "display": "In combination with ASA for patients with: ST-elevated myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI) who have not received antiplatelet therapy prior to arrival in the catheterization lab OR Acute coronary syndrome who failed on optimal clopidogrel and ASA therapy as defined by definite stent thrombosis, or recurrent STEMI, or NSTEMI or UA after prior revascularization via PCI.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "In combination with ASA for patients with: ST-elevated myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI) who have not received antiplatelet therapy prior to arrival in the catheterization lab OR Acute coronary syndrome who failed on optimal clopidogrel and ASA therapy as defined by definite stent thrombosis, or recurrent STEMI, or NSTEMI or UA after prior revascularization via PCI."
          }
        ]
      },
      {
        "abstract": false,
        "code": "450",
        "display": "In combination with everolimus, for the treatment of hormone-receptor positive HER2 negative advanced breast cancer, in postmenopausal women with ECOG performance status less than or equal to 2 after recurrence or progression following a non-steroidal aromatase inhibitor (NSAI).",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "In combination with everolimus, for the treatment of hormone-receptor positive HER2 negative advanced breast cancer, in postmenopausal women with ECOG performance status less than or equal to 2 after recurrence or progression following a non-steroidal aromatase inhibitor (NSAI)."
          }
        ]
      },
      {
        "abstract": false,
        "code": "451",
        "display": "For the seasonal treatment of grass pollen allergic rhinitis in patients that have not adequately responded to, or tolerated, conventional pharmacotherapy.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "For the seasonal treatment of grass pollen allergic rhinitis in patients that have not adequately responded to, or tolerated, conventional pharmacotherapy."
          }
        ]
      },
      {
        "abstract": false,
        "code": "452",
        "display": "In combination with a 5HT3 receptor antagonist and dexamethasone for highly emetogenic chemotherapy (HEC) regimens: Cisplatin-based chemotherapy where a single daily dose is greater than or equal to 70 mg per meter squared; Cisplatin and cyclophosphamide combinations where the single daily dose is greater than or equal to 50mg per meter squared; Cisplatin (any dose) given for 3 to 5 consecutive days; Non-cisplatin based highly emetogenic chemotherapy (such as those containing anthracycline greater than or equal to 60mg per meter squared plus cyclophosphamide)",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "In combination with a 5HT3 receptor antagonist and dexamethasone for highly emetogenic chemotherapy (HEC) regimens: Cisplatin-based chemotherapy where a single daily dose is greater than or equal to 70 mg per meter squared; Cisplatin and cyclophosphamide combinations where the single daily dose is greater than or equal to 50mg per meter squared; Cisplatin (any dose) given for 3 to 5 consecutive days; Non-cisplatin based highly emetogenic chemotherapy (such as those containing anthracycline greater than or equal to 60mg per meter squared plus cyclophosphamide)"
          }
        ]
      },
      {
        "abstract": false,
        "code": "453",
        "display": "For patients receiving moderately emetogenic chemotherapy (MEC) regimens AND who have had inadequate symptom control using a 5HT3 antagonist and dexamethasone in a previous cycle.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "For patients receiving moderately emetogenic chemotherapy (MEC) regimens AND who have had inadequate symptom control using a 5HT3 antagonist and dexamethasone in a previous cycle."
          }
        ]
      },
      {
        "abstract": false,
        "code": "454",
        "display": "For the treatment of emesis in cancer patients receiving moderately emetogenic chemotherapy (MEC) regimens.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "For the treatment of emesis in cancer patients receiving moderately emetogenic chemotherapy (MEC) regimens."
          }
        ]
      },
      {
        "abstract": false,
        "code": "455",
        "display": "For the treatment of symptomatic vitreomacular adhesion (VMA) that has been confirmed through optical coherence tomography.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "For the treatment of symptomatic vitreomacular adhesion (VMA) that has been confirmed through optical coherence tomography."
          }
        ]
      },
      {
        "abstract": false,
        "code": "456",
        "display": "For the long-term treatment of patients with moderate to severe chronic obstructive pulmonary disease (COPD) who have a history of exacerbations and have had an inadequate response to a long-acting bronchodilator (i.e., long-acting beta-2 agonist (LABA), or long-acting muscarinic antagonist (LAMA)).",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "For the long-term treatment of patients with moderate to severe chronic obstructive pulmonary disease (COPD) who have a history of exacerbations and have had an inadequate response to a long-acting bronchodilator (i.e., long-acting beta-2 agonist (LABA), or long-acting muscarinic antagonist (LAMA))."
          }
        ]
      },
      {
        "abstract": false,
        "code": "457",
        "display": "For the seasonal treatment of short ragweed pollen induced allergic rhinitis in patients that have not adequately responded to, or tolerated, conventional pharmacotherapy.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "For the seasonal treatment of short ragweed pollen induced allergic rhinitis in patients that have not adequately responded to, or tolerated, conventional pharmacotherapy."
          }
        ]
      },
      {
        "abstract": false,
        "code": "458",
        "display": "For persons suffering from New York Heart Association (NYHA) class II chronic heart failure with left ventricular systolic dysfuction (with ejection fraction less than or equal to 35 percent), as a complement to standard therapy.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "For persons suffering from New York Heart Association (NYHA) class II chronic heart failure with left ventricular systolic dysfuction (with ejection fraction less than or equal to 35 percent), as a complement to standard therapy."
          }
        ]
      },
      {
        "abstract": false,
        "code": "459",
        "display": "For the long-term treatment of patients with moderate to severe chronic obstructive pulmonary disease (COPD) who have had an inadequate response to a long-acting bronchodilator (i.e., long-acting beta-2 agonist (LABA), or long-acting muscarinic antagonist (LAMA)).",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "For the long-term treatment of patients with moderate to severe chronic obstructive pulmonary disease (COPD) who have had an inadequate response to a long-acting bronchodilator (i.e., long-acting beta-2 agonist (LABA), or long-acting muscarinic antagonist (LAMA))."
          }
        ]
      },
      {
        "abstract": false,
        "code": "460",
        "display": "For adult patients with urinary frequency, urgency or urge incontinence due to overactive bladder who have: Failed to respond to behavioral techniques AND had an inadequate response or intolerance to adequate trials (i.e., at least 2 weeks at the maximum tolerated dose) of at least two medications for overactive bladder (e.g. anticholinergics, mirabegron).",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "For adult patients with urinary frequency, urgency or urge incontinence due to overactive bladder who have: Failed to respond to behavioral techniques AND had an inadequate response or intolerance to adequate trials (i.e., at least 2 weeks at the maximum tolerated dose) of at least two medications for overactive bladder (e.g. anticholinergics, mirabegron)."
          }
        ]
      },
      {
        "abstract": false,
        "code": "461",
        "display": "In combination with a platinum-containing product and epirubicin for the treatment of advanced (non-resectable; either locally advanced or metastatic) gastric or gastro-esophageal junction cancer.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "In combination with a platinum-containing product and epirubicin for the treatment of advanced (non-resectable; either locally advanced or metastatic) gastric or gastro-esophageal junction cancer."
          }
        ]
      },
      {
        "abstract": false,
        "code": "462",
        "display": "For the treatment of patients with visual impairment due to choroidal neovascularization secondary to pathologic myopia.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "For the treatment of patients with visual impairment due to choroidal neovascularization secondary to pathologic myopia."
          }
        ]
      },
      {
        "abstract": false,
        "code": "463",
        "display": "For the treatment of patients with neovascular (wet) age-related macular degeneration (AMD) in a verteporfin PDT (Visudyne)-naive eye.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "For the treatment of patients with neovascular (wet) age-related macular degeneration (AMD) in a verteporfin PDT (Visudyne)-naive eye."
          }
        ]
      },
      {
        "abstract": false,
        "code": "464",
        "display": "For the treatment of patients with clinically significant macular edema secondary to central retinal vein occlusion (CRVO).",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "For the treatment of patients with clinically significant macular edema secondary to central retinal vein occlusion (CRVO)."
          }
        ]
      },
      {
        "abstract": false,
        "code": "465",
        "display": "For the treatment of patients with clinically significant diabetic macular edema (DME) for whom laser photocoagulation is also indicated; and a hemoglobin A1c of less than 12 percent.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "For the treatment of patients with clinically significant diabetic macular edema (DME) for whom laser photocoagulation is also indicated; and a hemoglobin A1c of less than 12 percent."
          }
        ]
      },
      {
        "abstract": false,
        "code": "466",
        "display": "As second-line therapy for patients who do not have an adequate intraocular pressure lowering response to monotherapy with brinzolamide or brimonidine.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "As second-line therapy for patients who do not have an adequate intraocular pressure lowering response to monotherapy with brinzolamide or brimonidine."
          }
        ]
      },
      {
        "abstract": false,
        "code": "467",
        "display": "For the treatment of moderate to severe signs and symptoms of uterine fibroids in adult women of reproductive age, who are eligible for surgery.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "For the treatment of moderate to severe signs and symptoms of uterine fibroids in adult women of reproductive age, who are eligible for surgery."
          }
        ]
      },
      {
        "abstract": false,
        "code": "468",
        "display": "For the treatment of rheumatoid arthritis (RA) in patients who have severe active disease (greater than or equal to 5 swollen joints and rheumatoid factor positive and/or, anti-CCP positive, and/or radiographic evidence of rheumatoid arthritis) and have experienced failure, intolerance, or have a contraindication to adequate trials of disease-modifying anti-rheumatic drugs (DMARDs) treatment regimens, such as one of the following combinations of treatments: Methotrexate (20mg/week) for at least 3 months, AND ii) leflunomide (20mg/day)for at least 3 months, in addition to iii) an adequate trial of at least one combination of DMARDs for 3 months; OR Methotrexate (20mg/week) for at least 3 months, AND ii) leflunomide in combination with methotrexate for at least 3 months; OR Methotrexate (20mg/week), sulfasalazine (2g/day) and hydroxychloroquine (400mg/day) for at least 3 months. (Hydroxychloroquine is based by weight up to 400mg per day.)",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "For the treatment of rheumatoid arthritis (RA) in patients who have severe active disease (greater than or equal to 5 swollen joints and rheumatoid factor positive and/or, anti-CCP positive, and/or radiographic evidence of rheumatoid arthritis) and have experienced failure, intolerance, or have a contraindication to adequate trials of disease-modifying anti-rheumatic drugs (DMARDs) treatment regimens, such as one of the following combinations of treatments: Methotrexate (20mg/week) for at least 3 months, AND ii) leflunomide (20mg/day)for at least 3 months, in addition to iii) an adequate trial of at least one combination of DMARDs for 3 months; OR Methotrexate (20mg/week) for at least 3 months, AND ii) leflunomide in combination with methotrexate for at least 3 months; OR Methotrexate (20mg/week), sulfasalazine (2g/day) and hydroxychloroquine (400mg/day) for at least 3 months. (Hydroxychloroquine is based by weight up to 400mg per day.)"
          }
        ]
      },
      {
        "abstract": false,
        "code": "469",
        "display": "For the treatment of ankylosing spondylitis (AS) in patients who have severe active disease (confirmed by radiographic evidence with: Age of disease onset less than or equal to 50; AND Low back pain and stiffness for greater than 3 months that improves with exercise and not relieved by rest; AND Failure to respond to or documented intolerance to adequate trials of 2 non-steroidal anti-inflammatory drugs (NSAIDs) for at least 4 weeks each; AND Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score of greater than or equal to 4 for at least 4 weeks while on standard therapy.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "For the treatment of ankylosing spondylitis (AS) in patients who have severe active disease (confirmed by radiographic evidence with: Age of disease onset less than or equal to 50; AND Low back pain and stiffness for greater than 3 months that improves with exercise and not relieved by rest; AND Failure to respond to or documented intolerance to adequate trials of 2 non-steroidal anti-inflammatory drugs (NSAIDs) for at least 4 weeks each; AND Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score of greater than or equal to 4 for at least 4 weeks while on standard therapy."
          }
        ]
      },
      {
        "abstract": false,
        "code": "470",
        "display": "For the treatment of psoriatic arthritis in patients who have severe active disease (greater than or equal to 5 swollen joints and radiographic evidence of psoriatic arthritis) despite: i) treatment with methotrexate (20mg/week) for at least 3 months; AND ii) one of leflunomide (20mg/day) or sulfasalazine (1g twice daily) for at least 3 months.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "For the treatment of psoriatic arthritis in patients who have severe active disease (greater than or equal to 5 swollen joints and radiographic evidence of psoriatic arthritis) despite: i) treatment with methotrexate (20mg/week) for at least 3 months; AND ii) one of leflunomide (20mg/day) or sulfasalazine (1g twice daily) for at least 3 months."
          }
        ]
      },
      {
        "abstract": false,
        "code": "471",
        "display": "For the treatment of severe plaque psoriasis in patients 18 years of age or older who have experienced failure, intolerance, or have a contraindication to adequate trials of several standard therapies.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "For the treatment of severe plaque psoriasis in patients 18 years of age or older who have experienced failure, intolerance, or have a contraindication to adequate trials of several standard therapies."
          }
        ]
      },
      {
        "abstract": false,
        "code": "977",
        "display": "Exceptional cases of allergy or intolerance to all other appropriate therapies.",
        "designation": [
          {
            "language": "en",
            "use": {
              "system": "http://snomed.info/sct",
              "code": "900000000000550004",
              "display": "Definition"
            },
            "value": "Exceptional cases of allergy or intolerance to all other appropriate therapies."
          }
        ]
      }
    ]
  }
}

name : PrescriptionODBReasonForUse

{

}